Skip to main content
Professional Technical IVT

adenosine deaminase deficiency

Genetic disorder causing severe combined immunodeficiency due to toxic accumulation of purine metabolites in lymphocytes.

Full Definition

Adenosine deaminase deficiency (ADA deficiency) is an autosomal recessive disorder that accounts for approximately 10-15% of severe combined immunodeficiency cases. The absence or reduction of ADA enzyme activity leads to accumulation of toxic purine metabolites, particularly deoxyadenosine triphosphate, which is selectively toxic to lymphocytes. This results in severe T-cell, B-cell, and NK cell deficiency. Beyond immunodeficiency, patients may develop skeletal abnormalities, sensorineural hearing loss, and cognitive impairment due to ADA's role in purine metabolism throughout the body.

Usage

Usage note: Often abbreviated as ADA deficiency; enzyme replacement therapy may be used as bridge to definitive treatment.

In Context

  • "Enzyme assay confirmed adenosine deaminase deficiency as the cause of the infant's severe combined immunodeficiency." — Laboratory report
  • "The patient with adenosine deaminase deficiency showed improvement in immune function following enzyme replacement therapy." — Follow-up note

Also known as

ADA deficiency ADA-SCID

Don't confuse with

purine nucleoside phosphorylase deficiency

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON